期刊文献+

射频消融联合胞嘧啶鸟嘌呤寡脱氧核苷酸治疗小鼠乳腺癌皮下模型 被引量:2

Therapy of subcutaneous models of breast cancer in miceby radiofrequency ablation combined with peritumoral injection of cytosine phosphate guanine oligodeoxyribonucleotide
原文传递
导出
摘要 目的观察射频消融联合瘤周注射胞嘧啶鸟嘌呤寡脱氧核苷酸(CpGODN)对BALB/c小鼠皮下种植性乳腺癌的治疗作用及对荷瘤鼠免疫功能的影响。方法32只BALB/c小鼠双侧胁肋部皮下接种乳腺癌细胞EMT-6,建立乳腺癌动物模型,随机分为4组,每组8只,分别给予左侧皮下肿瘤射频消融+瘤周注射CpGODN、射频消融、瘤周注射CpGODN和瘤周注射生理盐水4种处理。定期测量治疗侧及非治疗侧肿瘤大小,尾静脉取血法收集各组小鼠外周血,酶联免疫吸附试验(ELISA)法检测血清白细胞介素(IL)-12、IL-10、IL-2及干扰素(IFN)-γ含量。当非治疗侧肿瘤直径达到18mm时手术切除肿瘤,并记录为非治疗侧观察终点,当治疗侧肿瘤直径达到18min时或出现恶病质时处死小鼠,记录生存时间。结果射频消融+瘤周注射CpGODN组和射频消融组治疗侧肿瘤体积体积显著小于CpGODN组和对照组(P〈0.05)。射频消融+瘤周注射CpGODN组未治疗侧的肿瘤体积在第21天后明显小于其他各组(P〈0.05)。射频消融+瘤周注射CpGODN组中位生存时间为92d,射频消融组为84d,瘤周注射CpGODN组为64d,对照组为60d。射频消融+瘤周注射CpGODN组小鼠外周血中IL—12浓度为312.40ng/L,IL-10浓度为216.34ng/L,IL-2浓度为75.33ng/L,IFN-γ浓度为69.32ng/L,显著高于其他3组(P〈0.05)。结论射频消融联合瘤周注射CpGODN能激活小鼠体内的抗肿瘤免疫效应,起到抑制肿瘤生长作用。 Objective To investigate the efficacy of microwave ablation combined with peritumoral injected cytosine phosphate guanine oligodeoxyribonucleotide (CpG ODN) in inducing immunityresponse against mouse breast cancer. Methods Bilateral breast cancer model was established by subcutaneous injec- tion EMT - 6 ceils underneath both sides of the BALB/c mouse rib area. According the therapy method to the left side tumor, there were 32 mice were divided randomly into four groups: combination therapy group (mi- crowave ablation combined with peritumoral injected CpG ODN), ablation therapy group, CpG ODN therapy group, and control group. Bilateral tumor volume and survive time were observed. Concentration of interleu- kin (IL) -12, IL- 10, IL- 2 and interferon (IFN) -γ in serum were detected by enzyme linked immu- nosorbent assay (ELISA) method. When the non- treatment side tumor reaches 18 mm in diameter, the tumor resection is carried on, and recorded as endpoint of this side. When the treatment side tumor reaches 18 mm in diameter or cachexia takes place, the mice will be kilIed and the survival time will be recorded. Results In the bilateral tumor model, the left tumor volumes in combination therapygroup and ablation ther- apy group were smaller than those in CpG ODN therapy group and control group, right tumor volumes in com- bination therapygroup were smaller than those in other group after 21 days. The median survive time in com- bination therapy group, ablation therapy group, CpG ODN therapy group, and control group were 92, 84, 64, 60 days respectively. The serum concentrations of IL - 2, IL - 10, IL - 12, IFN -γ in combination ther- apy group were higher than those in other groups. Conclusion Microwave ablation combined with peritu- moralinjection of CpG ODN can enhance the host antitumor iinmunityeffect and inhibit tumor growth.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2015年第8期1869-1871,共3页 Chinese Journal of Experimental Surgery
基金 广东省科技计划资助项目(20128061700065) 广东省医学科研基金资助项目(B2012191)
关键词 射频消融 胞嘧啶鸟嘌呤寡脱氧核苷酸 乳腺癌 免疫治疗 Ablation Cytosine phosphate guanine oligodeoxyribonucleotide Breast cancer Immunotherapy
  • 相关文献

参考文献14

  • 1Den Brok MH,Sutmuller RP,van der Voort R,et al.In situ tumor ablation creates an antigen source for the generation of antitumor immunity[J].Cancer Res,2004,64(11):4024-4029.
  • 2Wissniowski TT,Hansler J,Neureiter D,et al.Activation of tumorspecific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits[J].Cancer Res,2003,63(19):6496-6500.
  • 3Haen SP,Pereira PL,Salih HR,et al.More than just tumor destruction:immunomodulation by thermal ablation of cancer[J].Clin Dev Immunol,2011,2011:160250.
  • 4Haen SP,Gouttefangeas C,Schmidt D,et al.Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation[J].Cell Stress Chaperones,2011,16(5):495-504.
  • 5Widenmeyer M,Shebzukhov Y,Haen SP,et al.Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation[J].Int J Cancer,2011,128 (11):2653-2662.
  • 6Schueller G,Stift A,Friedl J,et al.Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells[J].Int J Oncol,2003,22(6):1397-1402.
  • 7Behboudi S,Chao D,Klenerman P,et al.The effects of DNA containingCpG motif on dendritic cells[J].Immunology,2000,99 (3):361-366.
  • 8Zhou PJ,Ma BB,He W,et al.CpGoligodeoxynucleotide stimulates protective innate immunity against human renal cell carcinoma xenografted in nude mice[J].J Immunother,2011,34(7):535-541.
  • 9Wong KL,Tang LF,Lew FC,et al.CD44high memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production[J].J Immuno1,2009,183 (1):41-50.
  • 10Chen L,Jondal M.Alternative processing for MHC class Ⅰ presentation by immature and CpG-activated dendritic cells[J].Eur J Immunol,2004,34(4):952-960.

二级参考文献21

  • 1谭进富,吕明德,刘大全,王竹,周忠信,黄洁夫.微波消融肝癌对小鼠细胞免疫的影响[J].中国病理生理杂志,2006,22(6):1214-1217. 被引量:10
  • 2任师颜,徐力善,周宁新,董宝玮.增强肝癌微波热消融的疗效[J].肝胆外科杂志,2006,14(4):312-314. 被引量:2
  • 3Arthur MK. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer[J]. Oncogene, 2008, 27: 161-7.
  • 4Arthur MK. Development of TLR9 agonists for cancer therapy [ J ]. J Clin Invest, 2007, 117:1184 -94.
  • 5Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses[J ]. Nat Immunol, 2004, 5: 987-95.
  • 6Lonsdorf AS, Kuekrek H, Stem BV, et al. Intratumor CpG- oligodeoxynucleotide injection induces protective antitumor T cell immunity[J]. J lmmunol, 2003, 171: 3941-6.
  • 7Achim S, Christine W, Anja Z, et al. CpG motifs are efficient adjuvants for DNA cancer vaccines [J]. J Invest Dermatol, 2004, 123: 371-9.
  • 8Rebecca LV, Thomas SG. Activation of tumor-specific CD8T cells after intratumoral Ad5 - TRAIL/CpG oligodeoxynucleotide combination therapy[J]. Cancer Res, 2007, 67(24): 11980-90.
  • 9Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in murine colon carcinoma model [J]. J lmmnnol, 2002, 169: 3892-9.
  • 10Carpentier A, Laigle-Donadey F, Zohar S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma [J]. Neurol Oncol, 2006, 8: 60-6.

共引文献4

同被引文献47

  • 1Noguchi M. Role of breast surgeons in evolution of the surgical management of breast cancer [J]. Breast Cancer, 2007, 14(1) : 1-8.
  • 2Noguehi M. Radiofrequency ablation treatment for breast cancer to meet the next challenge :how to treat primary breast tumor without surgery[J].Breast Cancer,2003,10(1): 1-3. Noguchi M. Minimally invasive surgery for small breast eaneer[J].J Surg Oneol, 2003,84(2) :94-101.
  • 3Van der Ploeg IM,van Esser S,van den Bosch MA,et al. Radiofrequency ablation for breast eaneer:a review of the literature[J]. EJSO, 2007,33(6) : 673-677.
  • 4Van der Ploeg IM,van Esser S,van den Bosch MA,et al. Radiofrequency ablation for breast cancer: a review of the literature[J]. EJSO, 2007,33(6) : 673-677.
  • 5Dickson JA,Calderwood SK. Temperature range and se- lective sensitivity of tumors to hyperthermia:a critical re- view[J]. Ann NY Acad Sci, 1980,335:180-205.
  • 6Tannock IF,Bristow RG,Hill RP,et al. The basic science of oncology[M]. New York:Pergamon Press, 1987. 337-357.
  • 7Haines DE,Watson DD,Halperin C. Characteristics of heat transfer and determination of temperature gradient and viability threshold during radiofrequency fulguration of isolated perfused canine right ventricle [J]. Circulation, 1987,76 : 278-282.
  • 8Steeves RA. Hyperthermia in cancer therapy :where are we today and where are we going?[J]. Bull NY Acad Med, 1992,68(2) : 341-350. Bischof J,Christov K, Rubinsky B. A morphological study of cooling rate response in normal and neoplastic human liver tissue:cryosurgical implications [J]. Cryobiology, 1993,30(5) : 482-492.
  • 9Haines DE. The pathophysiology of radiofrequency lesion formation[A].Catheter ablation of arrhythmias[M]. Armonk, NY :Futura Publishing Co. Inc, 1994.105-127.
  • 10Izzo F,Thomas R, Delrio P, et al. Radiofrequency ablation in patients with primary breast carcinoma:a pilot study in 26 patients[J]. Cancer, 2001,92(8) :2036-2044.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部